OBJECTIVE: To perform a population-based analysis to compare the complications and cost of laparoscopic and robotically assisted adnexal surgery. METHODS: A nationwide database was used to analyze the use and outcomes of robotically assisted adnexal surgery from 2009 to 2012. Multivariable mixed effects regression models were developed to examine predictors of use of robotic surgery. After propensity score matching, complications and cost were compared between robotically assisted and laparoscopic surgery. RESULTS: Eighty-seven thousand five hundred fourteen women were identified. From 2009 to 2012, performance of robotic-assisted oophorectomy increased from 3.5% (95% confidence interval [CI] 3.2-3.8%) to 15.0% (95% CI 14.4-15.6%), whereas robotically assisted cystectomy rose from 2.4% (95% CI 2.0-2.7%) to 12.9% (95% CI 12.2-13.5%). The overall complication rate was 7.1% (95% CI 4.0-10.2%) for robotically assisted compared with 6.0% (95% CI 2.9-9.1%) for laparoscopic oophorectomy (odds ratio [OR] 1.20, 95% CI 1.00-1.45; P=.052). Robotic-assisted oophorectomy was associated with a higher rate of intraoperative complications (3.4% compared with 2.1%, OR 1.60, 95% CI 1.21-2.13). The overall complication rate was 3.7% (95% CI -0.8 to 8.2%) after robotically assisted compared with 2.7% (95% CI -1.8 to 7.2%) for laparoscopic cystectomy (OR 1.38, 95% CI 0.95-1.99). The intraoperative complication rate was higher for robotically assisted cystectomy (2.0% compared with 0.9%, OR 2.40, 95% CI 1.31-4.38). Compared with laparoscopy, robotically assisted oophorectomy was associated with $2,504 (95% CI $2,356-2,652) increased total costs and robotically assisted cystectomy $3,310 (95% CI $3,082-3,581) higher costs. CONCLUSION: Use of robotically assisted adnexal surgery increased rapidly. Compared with laparoscopic surgery, robotically assisted adnexal surgery is associated with substantially greater costs and a small, but statistically significant, increase in intraoperative complications.
OBJECTIVE: To perform a population-based analysis to compare the complications and cost of laparoscopic and robotically assisted adnexal surgery. METHODS: A nationwide database was used to analyze the use and outcomes of robotically assisted adnexal surgery from 2009 to 2012. Multivariable mixed effects regression models were developed to examine predictors of use of robotic surgery. After propensity score matching, complications and cost were compared between robotically assisted and laparoscopic surgery. RESULTS: Eighty-seven thousand five hundred fourteen women were identified. From 2009 to 2012, performance of robotic-assisted oophorectomy increased from 3.5% (95% confidence interval [CI] 3.2-3.8%) to 15.0% (95% CI 14.4-15.6%), whereas robotically assisted cystectomy rose from 2.4% (95% CI 2.0-2.7%) to 12.9% (95% CI 12.2-13.5%). The overall complication rate was 7.1% (95% CI 4.0-10.2%) for robotically assisted compared with 6.0% (95% CI 2.9-9.1%) for laparoscopic oophorectomy (odds ratio [OR] 1.20, 95% CI 1.00-1.45; P=.052). Robotic-assisted oophorectomy was associated with a higher rate of intraoperative complications (3.4% compared with 2.1%, OR 1.60, 95% CI 1.21-2.13). The overall complication rate was 3.7% (95% CI -0.8 to 8.2%) after robotically assisted compared with 2.7% (95% CI -1.8 to 7.2%) for laparoscopic cystectomy (OR 1.38, 95% CI 0.95-1.99). The intraoperative complication rate was higher for robotically assisted cystectomy (2.0% compared with 0.9%, OR 2.40, 95% CI 1.31-4.38). Compared with laparoscopy, robotically assisted oophorectomy was associated with $2,504 (95% CI $2,356-2,652) increased total costs and robotically assisted cystectomy $3,310 (95% CI $3,082-3,581) higher costs. CONCLUSION: Use of robotically assisted adnexal surgery increased rapidly. Compared with laparoscopic surgery, robotically assisted adnexal surgery is associated with substantially greater costs and a small, but statistically significant, increase in intraoperative complications.
Authors: Michael B Rothberg; Penelope S Pekow; Maureen Lahti; Oren Brody; Daniel J Skiest; Peter K Lindenauer Journal: JAMA Date: 2010-05-26 Impact factor: 56.272
Authors: George J Stukenborg; Kerry L Kilbridge; Douglas P Wagner; Frank E Harrell; M Norman Oliver; Jason A Lyman; Jonathan S Einbinder; Alfred F Connors Journal: Surgery Date: 2005-09 Impact factor: 3.982
Authors: Jason D Wright; Alfred I Neugut; Elizabeth T Wilde; Donna L Buono; Wei-Yann Tsai; Dawn L Hershman Journal: J Oncol Pract Date: 2012-06-19 Impact factor: 3.840
Authors: Jason D Wright; William M Burke; Elizabeth T Wilde; Sharyn N Lewin; Abigail S Charles; Jin Hee Kim; Noah Goldman; Alfred I Neugut; Thomas J Herzog; Dawn L Hershman Journal: J Clin Oncol Date: 2012-01-30 Impact factor: 44.544
Authors: Jason D Wright; Cande V Ananth; Sharyn N Lewin; William M Burke; Yu-Shiang Lu; Alfred I Neugut; Thomas J Herzog; Dawn L Hershman Journal: JAMA Date: 2013-02-20 Impact factor: 56.272
Authors: Jim C Hu; Xiangmei Gu; Stuart R Lipsitz; Michael J Barry; Anthony V D'Amico; Aaron C Weinberg; Nancy L Keating Journal: JAMA Date: 2009-10-14 Impact factor: 56.272
Authors: Esther H Chung; Stephanie L Lim; Evan Myers; Haley A Moss; Kelly S Acharya Journal: J Assist Reprod Genet Date: 2021-05-11 Impact factor: 3.357
Authors: Catherine A Shu; Malcolm C Pike; Anjali R Jotwani; Tara M Friebel; Robert A Soslow; Douglas A Levine; Katherine L Nathanson; Jason A Konner; Angela G Arnold; Faina Bogomolniy; Fanny Dao; Narciso Olvera; Elizabeth K Bancroft; Deborah J Goldfrank; Zsofia K Stadler; Mark E Robson; Carol L Brown; Mario M Leitao; Nadeem R Abu-Rustum; Carol A Aghajanian; Joanne L Blum; Susan L Neuhausen; Judy E Garber; Mary B Daly; Claudine Isaacs; Rosalind A Eeles; Patricia A Ganz; Richard R Barakat; Kenneth Offit; Susan M Domchek; Timothy R Rebbeck; Noah D Kauff Journal: JAMA Oncol Date: 2016-11-01 Impact factor: 31.777